Taken together and with the observation that trastuzumab reduces the radioresistant S-phase fraction (14), these results suggest a HER2-targeted radiopharmaceutical, such as the alpha-particle emitting thorium-227 trastuzumab conjugate, might have clinical benefit in patients with HER2-positive adenocarcinoma or adenosquamous carcinoma of the uterine cervix. The gene discussed is ERBB2; the disease is adenocarcinoma.